GLP1R and metabolic syndrome: Ghrelin is a potential marker of atherosclerosis Chronic inflammation Visceral fat is associated with frequency and severity of MetS Apparent protective role on the cardiometabolic profile High risk of T2D GLP-1 receptors agonists significantly decrease blood glucose and seem to reduce WC and BMI